Press Release (PharmiWeb)

More info…
HELSINKI, December 3 /PRNewswire/ — After two decades of scientifically and medically proven success in theirfield, Lightlake Therapeutics’ experts have been granted ethical approval tobegin selecting and gene testing subjects for a trial of a simple, safe andeffective treatment for what the World Health Organisation has described as aglobal epidemic of unhealthy eating and obesity.

naltrexone drug